Lupin has received an observation in the establishment inspection report given by the US health regulator for its Tarapur facility in Maharashtra. The inspection, conducted by the United States Food and Drug Administration (USFDA) between August 27 and August 31, concluded with an inspectional observation, Lupin said in a statement.
“For Lupin, meeting and exceeding global quality and procedural standards have always been paramount. We are committed to upholding the highest levels of quality and compliance standards across all our facilities,” said Lupin Managing Director Nilesh Gupta.
Founded in 1992, the Tarapur facility manufactures active pharmaceuticals ingredients. Shares of Lupin were trading at Rs 854.00 per scrip on the BSE, up 1.09 per cent, from their previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.